enzastaurin has been researched along with Carcinoma, Non-Small Cell Lung in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hannun, YA; Sadeghi, MM; Salama, MF | 1 |
| Cao, FF; Meng, FL; Wang, Y; Zhang, LL; Zhang, Y; Zhong, DS; Zhou, QH | 1 |
| Ciardiello, F; Gridelli, C; Laus, G; Martinelli, E; Morgillo, F; Pepe, S; Troiani, T | 1 |
| Giovannetti, E; Graff, JR; Peters, GJ; Sigmond, J; Smid, K; Tekle, C | 1 |
| Giaccone, G; Giovannetti, E; Hanauske, AR; Honeywell, R; Kuenen, B; Peters, GJ; Sigmond, J; Tekle, C | 1 |
| Barata, F; Barlesi, F; Bearz, A; Bepler, G; Chiappori, A; Chouaki, N; Iscoe, N; Liepa, AM; Park, K; Reck, M; Scagliotti, G; Soria, JC; von Pawel, J; Wagle, A; Zhao, YD | 1 |
| Bepler, G; Chen, T; Hofmann, J; Lee, SH; Zhou, J | 1 |
| Baldwin, JR; Koshiji, M; Kunitoh, H; Murakami, H; Nakamura, Y; Nokihara, H; Ohe, Y; Shukuya, T; Takahashi, T; Tamura, T; Tanai, C; Yamamoto, N | 1 |
| Allgayer, H; Körner, A; Manegold, C; Mudduluru, G | 1 |
| Asmar, L; Barrera, D; Bromund, J; Choksi, JK; Couch, LS; Jotte, R; Kocs, DM; Obasaju, CK; Patt, DA; Peng, G; Periman, PO; Pritchard, S; Raju, RN; Rousey, SR; Schlossberg, HR; Socinski, MA; Stinchcombe, T; Treat, J; Wang, Y; Weissman, CH | 1 |
| Chouaki, N; Eschbach, C; Kennedy, L; Ramlau, R; Reck, M; San Antonio, B; Szczesna, A; Vansteenkiste, J; Visseren-Grul, C; von Pawel, J | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Herbst, RS; Lahn, M; Oh, Y; Wagle, A | 1 |
| Fields, AP; Murray, NR | 1 |
| Bepler, G; Burris, H; Cleverly, A; Herbst, RS; Lahn, M; Musib, L; Oh, Y | 1 |
4 review(s) available for enzastaurin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Prognosis; Protein Isoforms; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras) | 2021 |
The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Indoles; Lung Neoplasms; Phosphorothioate Oligonucleotides; Protein Kinase C; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Survival Rate | 2015 |
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Pemetrexed | 2010 |
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors | 2007 |
6 trial(s) available for enzastaurin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Female; Folic Acid; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Salvage Therapy; Survival Rate; Vitamin B 12 | 2010 |
A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Pemetrexed; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life | 2010 |
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Placebos | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Immunoenzyme Techniques; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Salvage Therapy; Survival Rate | 2008 |
5 other study(ies) available for enzastaurin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Intracellular Space; Lung Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Signal Transduction | 2008 |
Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Drug Synergism; Folic Acid Antagonists; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Pemetrexed; Phosphorylation; Polymerase Chain Reaction; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2008 |
Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Phosphorylation; Polymorphism, Single Nucleotide; Protein Kinase C; Protein Kinase C beta; Signal Transduction; Small Cell Lung Carcinoma | 2010 |
Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Gene Knockdown Techniques; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleic Acid Hybridization; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Humans; Indoles; Isoenzymes; K562 Cells; Lung Neoplasms; Mice; Neoplasms; Oncogenes; Protein Kinase C; Rats; Signal Transduction | 2008 |